Scope of the Study
Bronchitis is a respiratory disease that causes inflammation of the bronchi in the lungs. It leads to wheezing, coughing, and difficulty breathing. In 2016, more than 8.9 million Americans were diagnosed with chronic bronchitis, and nearly 75% of cases involved people over the age of 45. In the United States, women have chronic bronchitis at almost double the rate of men. In 2016, 5.9 million women had been diagnosed with chronic bronchitis, as opposed to 3 million men who had been diagnosed during this time. Furthermore, a significant increase in respiratory disorders along with alarming rise in chemical pollutants is generating huge opportunities for the growth of the bronchitis treatment market.
The market study is being classified by Type (Acute Bronchitis and Chronic Bronchitis) and major geographies with country level break-up. According to AMA, the Global Bronchitis Treatment market is expected to see growth rate of 4.1%
AstraZeneca plc (United Kingdom), Novartis International AG (Switzerland), GlaxoSmithKline plc (United Kingdom), Dr. Reddy's Laboratories Ltd. (India), Melinta Therapeutics (United States), Sanofi S.A (France), Boehringer Ingelheim International GmbH (Germany) and Pfizer Inc. (United States) are some of the key players profiled in the study.
The bronchitis treatment market consists of few established players accounting for the major market shares. The entry of private-labels in the market will increase competition in among the existing providers in market to provide advance treatment services to maintain their sustainability through unique and clear propositions. Research Analyst at AMA predicts that United States and European Players will contribute to the maximum growth of Global Bronchitis Treatment market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Bronchitis Treatment market by Type, Application and Region.
On the basis of geography, the market of Bronchitis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Rise In Geriatric Population With Increased Incidence Of Bronchitis
- Increased Prevalence Of Respiratory Diseases Such As COPD Cases
- Increasing Trend Of Smoking In The Young Generation
- Patent Expiry of Key Drugs
- Sedentary Standard Of Living And Availability Of Treatment For Bronchitis
- Rise In The Sale Of Over-The-Counter Bronchitis Therapeutics
- Lack of Awareness in Rural Areas
Key Target AudienceNew Entrants/Investors, Analysts and Strategic Business Planners, Bronchitis Treatment Providers, Hospitals and Healthcare Firms, Government Regulatory and Research Organizations and End Users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase